How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

With reverse purchase financing, older homebuyers can increase their purchasing power with fewer financial limitations as they move towards retirement.

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Doug Mahoney Doug Mahoney is a writer covering home-improvement topics, ...